Primary cutaneous diffuse large B-cell lymphoma, NOS and leg type: Clinical, morphologic and prognostic differences.

Area of Science:

• Hematology
• Oncology
• Dermatology

Background:

• Primary cutaneous diffuse large B-cell lymphoma, not otherwise specified (PCLBCL/NOS) is a rare B-cell lymphoma with limited available data.
• Distinguishing PCLBCL/NOS from PCLBCL, leg type (PCLBCL/LT) is crucial for accurate diagnosis and prognosis.

Purpose of the Study:

• To identify clinical and immunohistochemical markers that characterize PCLBCL/NOS.
• To differentiate PCLBCL/NOS from PCLBCL/LT.
• To assess the clinical course and prognosis of PCLBCL/NOS.

Main Methods:

• Comparison of Bcl-2-negative PCLBCL/NOS cases (n=14) with Bcl-2-positive PCLBCL/LT cases (n=29).
• Analysis of clinical presentation, tumor characteristics, and survival data.
• Evaluation of immunohistochemical markers including Bcl-2, Ki67, CD3, and Bcl-6.

Main Results:

• PCLBCL/NOS patients were younger, predominantly male, and exhibited better survival rates compared to PCLBCL/LT patients.
• PCLBCL/NOS cases presented with larger, localized plaques, while PCLBCL/LT cases showed disseminated lesions.
• Higher proliferation rate (Ki67) was observed in PCLBCL/LT, and a more prominent CD3+ infiltrate in PCLBCL/NOS.
• Female gender and Bcl-2 expression correlated with worse survival; Bcl-6 expression and centroblastic subtype correlated with better outcomes.

Conclusions:

• PCLBCL/NOS and PCLBCL/LT exhibit distinct clinical behaviors and outcomes.
• Bcl-2 remains the primary marker for differentiating these PCLBCL subtypes.
• Bcl-2, female gender, and Bcl-6 are significant prognostic markers for primary cutaneous diffuse large B-cell lymphoma.